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Background: Currently, there are no effective medical treatment options to prevent the formation of heterotopic
bones in fibrodysplasia ossificans progressiva (FOP). By the drug repositioning strategy, we confirmed that
perhexiline maleate (Pex) potentially ameliorates heterotopic ossification in model cells and mice. Here, we
conducted a prospective study to assess the efficacy and safety of Pex in the treatment of FOP patients.
Methods: FOP patients in this open-label single-center study were treated with Pex for a total of 12 months, and
followed up for 12 consecutive months after medication discontinuation. The safety of the treatment was assessed
regularly by physical and blood examinations. The efficacy of Pex for preventing heterotopic ossifications was
evaluated by the presence of flare-ups, measurements of serum bone markers, and changes in the total bone
volume calculated by the three-dimensional computed tomography (3D-CT) images.
Results: Five patients with an average age of 23.4 years were enrolled. Within safe doses of Pex administration in
each individual, there were no drug-induced adverse effects during the medication phase. Three patients showed
no intense inflammatory reactions during the study period, while two patients had acute flare-ups around the hip
joint without evidence of trauma during the medication phase. In addition, one of them became progressively
incapable of opening her mouth over the discontinuation phase. Serum levels of alkaline phosphatase (ALP) and
bone specific ALP (BAP) were significantly and synchronously increased with the occurrence of flare-ups. Volumetric
3D-CT analysis demonstrated a significant increase in the total bone volume of Case 2 (378 cm3) and Case 3
(833 cm3) during the two-year study period.
Conclusions: We could not prove the efficacy of oral Pex administration in the prevention of heterotopic ossifications
in FOP. Serum levels of ALP and BAP appear to be promising biomarkers for monitoring the development of ectopic
ossifications and efficacy of the therapy. Quantification of change in the total bone volume by whole body CT
scanning could be a reliable evaluation tool for disease progression in forthcoming clinical trials of FOP.
Keywords: Fibrodysplasia ossificans progressiva, Perhexiline maleate, Clinical trial, Biomarker, Whole body CTBackground
Fibrodysplasia ossificans progressiva (FOP) (OMIM:
135100) is a severely disabling heritable disorder of con-
nective tissue characterized by congenital malforma-
tions of the great toes and progressive heterotopic
ossification in various extraskeletal sites. FOP is very* Correspondence: hkitoh@med.nagoya-u.ac.jp
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reproduction in any medium, provided the orrare with a worldwide prevalence of approximately 1/
2,000,000 [1]. It is caused by a recurrent activating mu-
tation (617G > A, R206H) in the gene encoding activin
A receptor type I (ACVR1)/activin-like kinase 2 (ALK2),
a bone morphogenetic protein (BMP) type I receptor
[2]. In FOP, the mutant receptor causes up-regulation of
a transcriptional factor, Id1. Typically, during the first
decade of life, sporadic episodes of painful soft tissue
swellings (flare-ups) occur, which can transform skeletal
muscles, tendons, ligaments, fascia, and aponeurosestd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sifications span the joints, lock them in place, and
render movement impossible [4]. Immobility is cumu-
lative and most patients are wheelchair-bound by the
end of second decade of life [5]. Attempts to remove
heterotopic bones usually lead to explosive new bone
formation.
At present, there is no definitive pharmacotherapy to
prevent progressive heterotopic ossifications in FOP.
Recently, dorsomorphin and LDN-193189, a selective
inhibitor of BMP type I receptor kinases, have been
reported to inhibit activation of the BMP signaling in
cultures cells and mice [6,7]. Similarly, CD1530, an
agonist of nuclear retinoic acid receptor-γ, prevented
heterotopic ossification in FOP model mice [8]. None
of these compounds, however, has been applied in cli-
nical practice.
A promising alternative for orphan diseases is the
drug repositioning strategy, in which a drug currently
used for patients with a specific disease is applied to
another disease [9]. The advantage of this strategy is
that the identified drugs are readily available and the
adverse effects are known. In order to search for clinic-
ally applicable drugs for FOP, we screened 1040 FDA-
approved drugs for suppression of the Id1 promoter
activated by the mutant ACVR1/ALK2 in mouse C2C12
myoblasts. We found that perhexiline maleate (Pex),
which is a prophylactic antianginal drug widely used
for stable angina but its use markedly declined in the
early 1980s after reports of hepatotoxicity and periph-
eral neuropathy, suppressed the Id1 promoter activity
and mRNA expression of native Id1 and alkaline phos-
phatase by down-regulating phosphorylation of Smad1/
5/8. Pex also reduced the volume of heterotopic ossifi-
cation in crude BMP-induced model mice [10]. Here,
we conducted an open-labeled clinical trial of Pex ad-
ministration in the management of FOP.
Methods
This study was a non-randomized, non-placebo-controlled
investigation to prospectively estimate the effect of Pex
treatment in FOP patients. Eligible for participation
were the patients who presented classic features of
FOP including congenital malformation of the great
toes and progressive heterotopic ossification of soft tis-
sues, and those who had R206H mutation in the
ACVR1/ALK2 gene [11]. Because safety of Pex admin-
istration in children has not been established, ske-
letally immature patients were excluded from the
study. Since there is no known effective treatment in pre-
venting heterotopic ossification of FOP, we did not exclude
the patients who received concurrent use of other medi-
cations, such as nonsteroidal anti-inflammatory drugs
(NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors. Afterapproval from the Institutional Review Boards of the
Nagoya University, patients who provided written in-
formed consent were enrolled in the study.
All patients continued to receive Pex administration
for a total of 12 months. At the end of this period, they
discontinued Pex pharmacotherapy and were moni-
tored for 12 consecutive months of discontinuation
follow-up phase. After two weeks administration of an
initial dose of 100 mg/day, plasma concentration of
Pex was measured to adjust the dosage in each in-
dividual. Therapeutic drug monitoring was then regu-
larly performed during the medication phase by Drs.
John D. Horowitz and Benedetta C. Sallustio (Queen
Elizabeth Hospital, Woodville, Australia), and an opti-
mal dose of oral Pex administration was individually
determined based on a range for Pex of 0.15-0.60 mg/
L. The Safety of treatment was assessed by a monthly
physical examination and a complete blood count/
serum chemistry evaluation every three months, with a
special care for known adverse effects of Pex including
peripheral neuropathy and drug induced hepatic dys-
function [12]. The efficacy of Pex for preventing het-
erotopic ossifications was evaluated clinically and
biochemically, as well as by volumetric computed tom-
ography (CT). Careful physical examination was
performed on each patient to observe the presence of
flare-ups and the development of new ectopic ossifica-
tions. Serum concentrations of non-specific alkaline
phosphatase (ALP), bone-specific alkaline phosphatase
(BAP) and osteocalcin (OC) were measured at baseline,
after 1, 3, 6, 9, and 12 months of Pex treatment (M:
medication phase), and after 1, 3, 6, 9, and 12 months
of medication discontinuation (D: discontinuation
phase), using the commercially available Japan Society of
Clinical Chemistry (JSCC) method, enzyme immunoassay
(EIA), and radioimmunoassay (RIA) respectively (SRL Inc,
Japan). For quantitative evaluation of ectopic bones to be
formed, whole body scanning by 16 slice multi-detector
CT was performed before the intervention (baseline), at
the end of Pex medication (M-12 m: 12 months after
commencement of treatment), and at the end of the
study (D-12 m: 12 months after medication discontinu-
ation). Due to various degrees of contractures in the
upper and lower extremities as well as in the trunk, the
top of the skull or periphery of the limbs sometimes
failed to be imaged in some patients. Thus, we defined
structural regions of interest (ROI) as the maximum
3D-CT imaging ranges to be analyzable which was stan-
dardized in each individual. Based on 3D-CT images,
total bone volume (expressed as cm3) in each patient
was calculated by quantitative density analysis. The vol-
ume of newly formed bones was quantified by change in
the total bone volume during the medication and dis-
continuation phases.









1 36 Male 150 mg/d None None
2 26 Male 200 mg/d None M-7 m (right proximal thigh)
3 18 Female 75 mg/d None M-8 m (left hip), D-2 m
(right jaw)
4 18 Female 14 mg/d None None
5 19 Male 100 mg/d None None
Pex=Perhexiline maleate; M-7 m=Medication phase at 7 months.
M-8 m=Medication phase at 8 months;
D-2 m=Discontinuation phase at 2 months.
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Five FOP patients were enrolled in the study between
July 2010 and July 2012 (Table 1). There were three
males and two females with an average age of 23.4 years
(range, 18–36 years). All patients had significant
deformities associated with severely restricted mobility
of the spine and limbs. Two patients were confined to
a wheelchair and required assistance in performingFigure 1 Serial measurements of serum osteocalcin (a), alkaline phos
from 5 FOP patients. Serum levels of osteocalcin were maintained within
of ALP rapidly elevated at M-9 m in Cases 2 and 3 who showed acute flare
inflammation of her right jaw at D-2 m, had persistent higher ALP levels at
serum ALP levels.activities of daily living. Two patients received concur-
rent treatment with COX-2 inhibitor on a regular basis,
and three patients irregularly took fast-acting NSAIDs
when they felt pain. Under strictly controlling plasma
concentration of Pex within 0.15-0.60 mg/L, the steady
dosage of Pex varied between individuals from 14 mg/
day (100 mg/week) to 200 mg/day. No obvious drug-
induced adverse effects were found and no patients
discontinued Pex administration during the whole pe-
riod of treatment.
In three of the five patients, there were no intense in-
flammatory reactions associated with flare-ups during
the study period, although this could happen randomly
(Table 1). On the other hand, acute flare-ups were
observed in two patients (Cases 2 and 3) without evi-
dence of trauma during the medication phase (M-7 m
and M-8 m, respectively) and high-dose corticosteroid
treatment was administered in each patient at the
beginning of flare-ups according to the treatment
guidelines of International Fibrodysplasia Ossificans
Progressiva Association (IFOPA) [13]. These flare-ups
occurred in the right proximal thigh in Case 2 andphatase (ALP) (b) and bone-specific alkaline phosphatase (BAP) (c)
the normal range during the study period in all patients. Serum levels
-ups at M-7 m and M-8 m, respectively. Case 3, who showed acute
D-3 m. Changes in serum BAP activity positively correlated to those in
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their hip joint mobility gradually deteriorated. In ad-
dition, Case 3 complained of severe right jaw pain and
subsequent difficulty in mouth opening during the
early discontinuation phase (D-2 m). Limited opening
of the mouth resulted in interference with eating and
oral hygiene.
Serum concentration of OC had no significant change
in all patients (Figure 1a). During the whole study
period, serum ALP and BAP levels were maintained at
a normal range in the three patients who did not have
inflammatory reactions. In the other two patients
(Cases 2 and 3), on the other hand, these bone mar-
kers significantly and synchronously elevated follow-
ing the occurrence of flare-ups during medication
phase (Figure 1b,c). Elevated ALP and BAP levels were
gradually reduced with time, but in Case 3, both boneFigure 2 Volumetric computed tomography (CT) examination. Represe
of Case 1 (a), and changes in total bone volume within the region of inter
increased 223 cm3 and 155 cm3 during the medication and discontinuatio
536 cm3 in the total bone volume during the medication and discontinuatmarkers rebounded with acute inflammation of her
right jaw during the early discontinuation phase.
Quantitative 3D-CT analysis demonstrated that the
total bone volume did not change in three patients
(Cases 1, 4, and 5) during the study period, while a sub-
stantial increase in the total bone volume, both during
the medication and discontinuation phases, was found
in two patients (Figure 2a,b). In Case 2, increased bone
volume of 223 cm3 during the medication phase and
that of 155 cm3 during the discontinuation phase
seemed to be associated with heterotopic bone for-
mations in the right adductor muscle, and around the
mid-femur, respectively (Figure 3a-g). In Case 3, there
was an increase of 297 cm3 in the total bone volume
during the medication phase, which seemed to be
related to intramuscular ossification in her left iliopsoas
(Figure 4a-d). She also showed a maximal increasedntative reconstructed 3D-CT image obtained by whole body scanning
ests (ROI) in each FOP patient (b). In Case 2, total bone volume has
n phases, respectively. In Case 3, there was an increase of 297 cm3 and
ion phases, respectively.
Figure 3 CT images from Case 2. Reconstructed 3D-CT images of the pelvis and bilateral femora at baseline (a), at M-12 m (c), and at D-12 m
(f). Axial CT images of the right hip at baseline (b), and at M-12 m (d), and those of the right mid-femur at M-12 m (e), and at D-12 m (g).
Heterotopic ossifications in the right adductor muscle (arrow) developed during the medication phase and around mid-femur developed during
the discontinuation phase ware clearly demonstrated.
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phase, which appeared to reflect maturation of the
iliopsoas ossification and newly developed bones in the
gluteus medius (Figure 4e-g) and around the right jaw
joints (Figure 4h,i).
Discussion
To date, there are few clinical trials in the treatment of
FOP. Zasloff et al. [14] conducted a prospective study to
assess the efficacy of isotretinoin (13-cis-retinoic acid) in
the prevention of heterotopic ossification in FOP, and
concluded that isotretinoin had no apparent effect in the
prevention of new bone formation after surgery or after
soft tissue trauma. Brantus and Meunier [15] evaluated
the effects of intravenous administration of etidronate
and oral corticosteroids for thirty-one FOP attacks in
seven patients, and observed 10 new ossifications
causing severe deterioration of joint mobility during
the mean six years of follow up. These studies indi-
cated that there is no proven efficacy with any therapy
in changing the natural history of the disease. Despite
the Pex treatment, heterotopic ossification developed
rapidly in our two patients suggesting that oral ad-
ministration of Pex within 0.15-0.60 mg/L seemed
to be unsatisfactory in the inhibition of heterotopicossifications in FOP. Moreover, there is a concerning
possibility that Pex administration unexpectedly in-
duced heterotopic ossification in these patients.
Abnormal biochemical measurements of bone min-
eral metabolism have rarely been reported in FOP [16].
Establishment of useful biomarkers as correlates of
disease severity and clinical outcome is desirable to
enable early proof-of-concept studies that can help
screen potential drug candidates and identify thera-
peutic targets. Kaplan et al. [17] described that serum
ALP activity may increase during disease flare-ups.
Our serial clinical and biochemical evaluations demon-
strated that elevation of serum ALP and BAP, which
synchronized with acute flare-ups, preceded the het-
erotopic new bone formations. Serum levels of ALP or
BAP could be useful biomarkers for monitoring the de-
velopment of heterotopic ossifications and efficacy of
the therapy in FOP.
Multi-detector-row CT has widely been used in clin-
ical environments, and whole body scanning allows 3D
structural characterization of entire bone segment at
high resolution [18]. Despite the restricted movement
and joint immobilization of our patients, standardi-
zation of ROI in each individual could allow for accur-
ate volume calculating capabilities. To the best of our
Figure 4 CT images form Case 3. Reconstructed 3D-CT images of the hip joints at baseline (a), at M-12 m (c), and at D-12 m (f). Axial CT
images of the left pelvis at baseline (b), at M-12 m (d, e), and at D-12 m (g), and those of the bilateral jaws at M-12 m (h), and at D-12 m (i).
Massive new bone formations in the left iliac muscle were developed during the medication phase (d, arrow). During the discontinuation phase,
the left intra-iliopsoas ossification matured (g, arrow), and heterotopic boned in the left gluteus medius (g, arrow head) and the right jaw joint
(i, arrow) were newly formed.
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sessment of ectopic bone formations in FOP. Volumet-
ric 3D-CT analyses demonstrated that change in the
total bone volume correlated with the clinical symp-
toms and laboratory examinations in two patients who
showed active flare-ups. Our study highlights greater
capabilities of whole body CT scanning as an evalu-
ation tool for disease progression in FOP, especially in
assessment of treatment efficacy during forthcoming
clinical trials.
There are several major limitations in the present study.
First, since there are no better natural history studies for
FOP to date, it is difficult to design any clinical trial with
meaningful endpoints. Furthermore, we do not know the
natural evolution of ectopic bone formations in our pa-
tients. Second, the present study could not be designed
for pediatric FOP patients because of uncertainty in safety,
tolerability, and pharmacokinetics of Pex in the pediatric
population. Third, heterotopic ossification in FOP is gen-
erally formed via an endochondral ossification process,
but we did not confirm heterotopic cartilage formation in
our patients. Quantification of total bone volume based
on 3D-CT images could be a reliable evaluation tool forassessment of ectopic bone formations, but radiation ex-
posure by CT examination may be a major issue for
young patients. Besides, whole body scanning has always
been uncomfortable for severely deformed FOP patients,
although it takes less than five minutes. Without scanning
the whole body, heterotopic ossification following flare-
ups (if they occur) could be evaluated by a narrow scan
around the flare-ups region. For future clinical trials,
standardization of imaging protocol will be expected in
evaluating heterotopic bones in FOP.
Conclusions
Although the number of patients is too small to draw re-
liable conclusions, oral administration of Pex within the
safety dose seemed not to be effective in the inhibition
of heterotopic ossifications in FOP, despite the absence
of significant adverse effects.
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